Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Next

(Sharecast News) - Analysts at Berenberg hiked their target price on retailer Next from 12,600.0p to 13,400.0p on Friday, noting the stock appeared to be in "a mid-market sweet spot". Berenberg noted that at Next's FY25 results meeting on 27 March, chief executive David Wolfson had pointed out that the firm had no "moat" - meaning that nothing in the business cannot be copied. However, Berenberg believes that building up a brand and business of Next's scale would take a long time.

Moreover, the German bank said Next's Total Platform - which offers end-to-end online selling services to brands and retailers, from website creation to delivery and returns - continues to be "unmatched" in the UK.

"Next is also fortunate in that it operates in the clothing and home mid-market sweet spot, which is relatively insulated from ultra-low-price competitors such as Shein and where the current trend is for consumers to seek better quality, even if they are buying fewer items," said Berenberg, which reiterated its 'buy' rating on the stock.

"Following the circa 11% rise in the share price in reaction to the increased sales and profit guidance that accompanied the full-year results, Next is trading on circa 16x price-to-earnings in the current year on our numbers, which is within its 20-year historical range of circa 6x to circa 18x."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.